Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced it has appointed Dr David Morris MD as Chief Medical Officer to lead the Company’s respiratory programmes.
In 2020 the BIA is supporting the award winning charity In2scienceUK in their mission to diversify the science sector and give those with the fewest opportunities the chance to gain the experience, confidence, skills and networks to support their future career in science.
In Gallagher’s state of the market report published in February 2019, we wrote that we did not expect market conditions to improve for the better in 2019. Unfortunately, that prediction has held, and as we enter into Q1 2020, the Directors’ and Officers’ (D&O) insurance market remains a difficult place in which to do business.
Steve Bates OBE, Chief Executive of the BioIndustry Association said: “For the UK life sciences sector to understand the benefit of any free trade deal we need to see the granular detail of what the UK hopes to achieve. Strengthening Intellectual Property regimes globally would benefit innovative UK life sciences businesses, so it is positive to see the Government recognises the importance of this issue in planning a US FTA.”
The UK officially left the E U last Friday. Today we saw greater clarity from both sides on how they plan to approach the upcoming negotiations about the future relationship. This morning’s speech by Boris Johnson, the Written Ministerial Statement and the new European Commission document authorising the opening of negotiations for a new partnership with the UK, together give an idea of where we might be headed and some of the obstacles to reaching agreement.
Despite the rollercoaster political backdrop since the referendum result the UK biotech sector is heading into the new decade and life outside the EU in a very strong position. As the BIA’s recently launched annual finance report showed, 2019 was the third best year recorded and the fifth consecutive year in which more than £1bn was raised. It’s clear that UK biotech companies remain an attractive investment opportunity for global investors.